{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88","upperLimit":"100","value":"96"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"}]}],"title":"At 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88","upperLimit":"100","value":"96"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"}]}],"title":"At 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80","upperLimit":"100","value":"91"},{"groupId":"OG001","lowerLimit":"38","upperLimit":"100","value":"67"}]}],"title":"At 24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Percentage of patients remaining alive estimated according to the Kaplan-Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.\n\npharmacological study: Correlative studies\n\nrituximab: Given IV\n\ndexamethasone: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"No Previous Treatment"},{"description":"Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.\n\npharmacological study: Correlative studies\n\nrituximab: Given IV\n\ndexamethasone: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Previous Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 6 months, 12 months and 24 months after enrollment","title":"Survival","type":"SECONDARY","unitOfMeasure":"Kaplan-Meier estimated % of patients"}